IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc., joins more than 50 other health care leaders in voicing its strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. The CREATES Act addresses delay tactics used by brand manufacturers to block entry of generic drugs into the marketplace by allowing generic manufacturers to obtain relief for the delay tactics being used to prevent their entry.
“Vizient strongly supports the CREATES Act, which will help to slow out-of-control prescription drug spending and stop anti-competitive tactics that keep drug prices high for patients and providers,” said Dan Kistner, senior vice president, Vizient pharmacy solutions. “Equally important, this legislation will help speed the introduction of generic and biosimilar medicines into the marketplace which is a critical step in helping to slow the upward trajectory of drug costs and ultimately lowering prices for patients.”
Vizient applauds this legislation, which will help improve access and affordability for the health care providers we serve, and help them fulfill their mission to provide high quality health care to their patients and communities.
Vizient is the nation’s largest health care performance improvement company serving a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health care delivery networks and non-acute health care providers.
About Vizient, Inc.
Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents more than $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, which was acquired in 2016. In 2017, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com as well as our newsroom, blog, Twitter, LinkedIn and YouTube pages for more information about the company.